Oesophageal Cancer: PET Does Not Improve Treatment
Cancer patients are often given chemo- or radiotherapy, with the aim of shrinking the tumour before it is surgically removed. PET is an imaging technique that makes a tumour in the oesophagus visible without the need for the patient to undergo an invasive examination. Especially during treatment cycles in which the tumour is supposed to shrink, it makes sense to check the tumour's response to the treatment. To date, however, no benefit for patients has ensued, according to Milly Schröer-Günther, MD, Institute for Quality and Efficiency in Healthcare (IQWiG), Cologne, Germany, and co-authors.
Dr. Schröer-Günther and colleagues conducted a systematic review of all available data to assess the benefit for patients of using PET to assess the response of oesophageal cancer to chemo- or radiotherapy. They searched the Medline, Embase, and Cochrane Library databases for randomised controlled trials (RCTs) and controlled clinical trials (CCTs) comparing PET with conventional techniques such as endosonography and computed tomography (CT). They did not find any RCTs or CCTs that addressed the question of the patient-relevant benefit of PET.
According to the researchers, the studies they have analysed have often investigated only a small number of patients or that their results are biased. Nevertheless, they say, PET carried out early on in treatment does have the potential to identify patients who will not respond to that treatment, and these patients could then be spared continuing treatment with its associated side effects. To reach this point, however, will require randomised controlled trials.
Source: Deutsches Ärzteblatt International
Image credit: Wikimedia Commons
Published on : Tue, 8 Sep 2015
The TE7 touch screen ultrasound system is designed to provide superior quality imaging for rapid patient-care decisions. Intuitive gesture controls and efficient focused point-of-care exams minimize the user learning curve, with no need to navigate a...
Digital electrocardiograph / 12-channel / with touchscreen CARDIOVIT FT-1 SCHILLER
Maximum performance in a compact electrocardiograph
SCHILLER’s latest innovation is ultra portable, has an intuitive 8-inch high-resolution multi-touch screen, an integrated thermal printer and is FDA approved. Designed for users who value state-of-the-art technology, the CARDIOVIT FT-1 is a networked...
Digital electrocardiograph / 16-channel / with touchscreen CARDIOVIT AT-170 SCHILLER
Robust design with high-performance
SCHILLER’s new high-end electrocardiograph AT-170 completes the proven AT product range. It offers robust design for the busiest hospitals, as well as a combination of applications that makes it the ideal multi-use workstation for private practices....
The new 3Dimensions™ Mammography System matches the unrivaled performance of our 3D Mammography™ exam, which is more accurate than conventional 2D mammograms, detecting 20-65% more invasive breast cancers. Breakthrough improvements transform the patient...
Based on Mindray's new generation ultrasound platform, mQuadro, M9 has raised the industry standards to an all new level. Advanced signal transmission and reception processors provide highly sensitive and accurate echo detection. Innovative transducer...